DBDaria V. Babushok

Daria V. Babushok

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daria V. Babushok has a total of 379 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification of human leukocyte antigen class I risk alleles and enriched T cell receptor groups in activated T cell pediatric acute liver failure

    by Catherine A. Chapin, Tamir Diamond, Joshua B. Wechsler, Samantha L. Gadd, Michelle Lau, Wenzhao Meng, Eline T. Luning Prak, Jamie L. Duke, Daria V. Babushok, Kathleen M. Loomes, et al.

    Objective: Activated T cell pediatric acute liver failure (TC‐PALF) is characterized by CD8+T cells in liver and peripheral blood. TC‐PALF patients are at increased risk of developing aplastic anemia (AA), an immune‐mediated disorder in which CD8+ T cells target hematopoietic stem and progenitor cells. Clonal expansion of T cell receptors (TCRs) and specific human leukocyte antigen (HLA) class I risk alleles have been reported in AA. We hypothesized TC‐PALF shares similar HLA associations and exhibits increased TCR clonality. Methods: Thirty‐one TC‐PALF and 15 other PALF diagnosis (other‐PALF) patients enrolled in the Pediatric Acute Liver Failure Study Group (PALFSG) were included. Liver tissue DNA underwent TCR β‐chain (TCRβ) complementarity‐determining region 3 sequencing and HLA genotyping. HLA allele frequencies were compared with ethnicity‐matched controls. TCR clonality was assessed and Grouping of Lymphocyte Interactions by Paratope Hotspots 2 (GLIPH2) was used to identify antigen‐convergent, disease‐associated TCR groups. Results: HLA class I alleles HLA‐A*23:01, HLA‐B*35:03, HLA‐B*52:01, and HLA‐B*39:05 were significantly overrepresented among TC‐PALF patients compared to ethnicity‐matched controls. Hepatic TCRβ clonality was increased in the TC‐PALF group. GLIPH2 identified 158 statistically significant TCR convergence groups enriched in TC‐PALF with significant HLA associations, representing putative antigen‐specific TCR clusters. Conclusions: Enrichment of specific HLA class I alleles, increased hepatic TCR clonality, and HLA‐associated TCR convergence groups support an HLA‐restricted, antigen‐driven CD8+ T cell response as a central mechanism of TC‐PALF. These findings provide a mechanistic framework for antigen discovery and future development of immunogenetic biomarkers to improve disease classification, risk stratification, and targeted immunomodulatory therapy.

  • Promoter TERT ‐ Related Hematopoietic Somatic Mosaicism in Patients With Telomere Biology Disorders

    by Madeline Franke, Rachel Kirchner, Bianca Barredo, Amar Zaidan, Sara Torres‐Esquius, Pamela Acha, Sandra Novoa‐Jáuregui, Maria Julia Montoro, Jane E. Churpek, Daria V. Babushok, et al.

  • High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia

    by Masanori Yoshida, Sushree S. Sahoo, Paula Y. Arnold, Carmelo Gurnari, Anaïs J. C. N. van Leeuwen, Limeng Pu, Markus J. van Roosmalen, Ti-Cheng Chang, Charnise Goodings, Rashid Mehmood, et al.

    Aplastic anemia (AA) results from T-cell-mediated destruction of hematopoietic stem and progenitor cells (HSPCs), driving clonal hematopoiesis via loss of human leukocyte antigen (HLA) risk alleles (HLA loss-of-function mutations or uniparental disomy 6p, UPD6p), paroxysmal nocturnal hemoglobinuria and clonal hematopoiesis of indeterminate potential (CHIP) mutations. Here genomic profiling of 619 patients with AA revealed clonal hematopoiesis in 69% of cases, with ASXL1, BCOR and BCORL1 identified as the most frequent CHIP mutations in pediatric cases. Single-cell multi-omics analysis of 304,902 cells from 48 samples uncovered complex branching clonal architecture, with a median of three HLA loss events per patient, converging to inactivate HLA risk alleles. Single-cell whole-genome sequencing (WGS) resolved up to 15 HLA loss clones per patient and phylogenetic reconstruction indicated that these clones originated years before diagnosis. Long-read WGS precisely mapped UPD6p breakpoints and HLA methylation. HLA loss conferred a protective effect against CHIP, evidenced by their near-absent co-occurrence. Longitudinal single-cell analysis demonstrated that long-lived clones were enriched in the CD34+ HSPC compartment. These findings reveal parallel evolutionary pathways used by hematopoietic cells to evade immune attack.


  • Open Access

    Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy

    by Britta Höchsmann, Gloria F. Gerber, Wilhelm Leopold, Bhumika J. Patel, Eleni Gavriilaki, Almut Hefter, Ursula Kalhammer, Sabine Opitz, Astrid Marx-Hoffmann, Daniel B. Knight, et al.

    Ravulizumab, a humanized, long-acting monoclonal antibody against complement factor C5, is a widely used treatment for paroxysmal nocturnal hemoglobinuria (PNH). Given that pregnant women with PNH are at increased risk for complications and the safety and efficacy of ravulizumab in pregnancy is not known, we performed an international multicenter retrospective analysis of 16 patients with PNH with 19 pregnancies managed with ravulizumab and compared outcomes to 8 earlier pregnancies in the same patients treated with eculizumab. Of the 8 eculizumab-treated pregnancies, 3 resulted in miscarriages and 1 in early preterm delivery for threatened fetal demise and massive fetal growth retardation. All 19 pregnancies on ravulizumab resulted in the birth of live infants, with a median gestational age of 267 days (interquartile range [IQR], 259-275) and median birth weight of 3115 g (IQR, 2458-3349). Cord blood testing in 2 pregnancies receiving intensified ravulizumab dosing revealed detectable ravulizumab levels consistent with transplacental transfer. After a median follow-up of 16.2 months (IQR, 4.4-40.1), no developmental abnormalities or severe infectious complications were observed in the children. This retrospective analysis provides evidence for the safety and effectiveness of ravulizumab in managing PNH during pregnancy and breastfeeding with favorable maternal and fetal outcomes.


  • Open Access

    Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults

    by Gabriel Aleixo, HeeJin Cheon, Jiayin Zheng, Stephanie Soewito, Jimmy Lee, Eléonore Kaphan, Neha Kalakuntla, Wei-Ying Jen, Sumasri Kotha, Alex Rupsee, et al.

    Acquired aplastic anemia (AA) can present similarly to inherited bone marrow failure syndromes (IBMFS) but treatment differs. AA diagnosis relies on excluding IBMFS; however, genetic testing is not always available, may delay care or be inconclusive. We developed the Predictive Aplastic Score System (PASS), a clinical tool using readily available data to distinguish AA from IBMFS in adults. The training cohort included 212 adults (162 AA, 50 IBMFS). Compared to IBMFS, AA patients were older and more likely to have acute-onset, severe cytopenias. Using logistic regression with LASSO, we selected seven clinical variables for model inclusion: severity, acuity, age, IBMFS red flags, AA-associated conditions, AA-associated somatic changes, and telomere lengths. The model achieved AUC of 0.990 (95% CI: 0.982–0.999), with 100% positive predictive value (PPV) for AA for scores ≥30. 86.8% of patients with scores <0 had IBMFS. We validated PASS in 716 patients from four external cohorts with AUC of 0.977 (95% CI: 0.968–0.987). Threshold analysis confirmed 100% PPV for scores ≥30, rapidly diagnosing 80% of AA cases. PASS is a practical and accurate clinical tool that can rapidly distinguish AA from IBMFS for most adult patients. To promote clinical adoption, we developed an open-access web calculator ( https://pennmedicine.shinyapps.io/passcalc/ ).

  • Open Access

    Development and Validation of the PASS Score: A Simplified Tool to Diagnose Acquired Aplastic Anemia in Adults

    by Gabriel Aleixo, HeeJin Cheon, Jiayin Zheng, Stephanie Soewito, Jimmy Lee, Eléonore Kaphan, Neha Kalakuntla, Wei-Ying Jen, Sumasri Kotha, Alex Rupsee, et al.

    Acquired aplastic anemia (AA) can present similarly to inherited bone marrow failure syndromes (IBMFS) but treatment differs. AA diagnosis relies on excluding IBMFS; however, genetic testing is not always available, may delay care or be inconclusive. We developed the Predictive Aplastic Score System (PASS), a clinical tool using readily available data to distinguish AA from IBMFS in adults. The training cohort included 212 adults (162 AA, 50 IBMFS). Compared to IBMFS, AA patients were older and more likely to have acute-onset, severe cytopenias. Using logistic regression with LASSO, we selected seven clinical variables for model inclusion: severity, acuity, age, IBMFS red flags, AA-associated conditions, AA-associated somatic changes, and telomere lengths. The model achieved AUC of 0.990 (95% CI: 0.982–0.999), with 100% positive predictive value (PPV) for AA for scores ≥ 30. 86.8% of patients with scores < 0 had IBMFS. We validated PASS in 716 patients from four external cohorts with AUC of 0.977 (95% CI: 0.968–0.987). Threshold analysis confirmed 100% PPV for scores ≥ 30, rapidly diagnosing 80% of AA cases. PASS is a practical and accurate clinical tool that can rapidly distinguish AA from IBMFS for most adult patients. To promote clinical adoption, we developed open-access web calculator (https://pennmedicine.shinyapps.io/passcalc/).


  • Open Access

    Clonal hematopoiesis in telomere biology disorders

    by Christopher M. Sande, Daria V. Babushok

  • Open Access

    Predicting secondary myeloid neoplasms in acquired aplastic anemia using machine learning models

    by Ahmet Celal Toprak, Mutlu Mete, Julia J. Shi, Daria V. Babushok, Carmelo Gurnari, Jaroslaw P. Maciejewski, Zoe Bass, Zehra Tombul, Carlos. I. A. Santos, Munevver N. Duran, et al.

  • Open Access

    ATM-dependent DNA damage response constrains cell growth and drives clonal hematopoiesis in telomere biology disorders

    by Christopher M. Sande, Stone Chen, Dana V. Mitchell, Ping Lin, Diana M. Abraham, Jessie Minxuan Cheng, Talia Gebhard, Rujul J. Deolikar, Colby Freeman, Mary Zhou, et al.

    Telomere biology disorders (TBDs) are genetic diseases caused by defective telomere maintenance. TBD patients often develop bone marrow failure and have an increased risk of myeloid neoplasms. To better understand the factors underlying hematopoietic outcomes in TBD, we comprehensively evaluated acquired genetic alterations in hematopoietic cells from 166 pediatric and adult TBD patients. Of these patients, 47.6% (28.8% of children, 56.1% of adults) had clonal hematopoiesis. Recurrent somatic alterations involved telomere maintenance genes (7.6%), spliceosome genes (10.4%, mainly U2AF1 p.S34), and chromosomal alterations (20.2%), including 1q gain (5.9%). Somatic variants affecting the DNA damage response (DDR) were identified in 21.5% of patients, including 20 presumed loss-of-function variants in ataxia-telangiectasia mutated ( ATM ). Using multimodal approaches, including single-cell sequencing, assays of ATM activation, telomere dysfunction-induced foci analysis, and cell-growth assays, we demonstrate telomere dysfunction–induced activation of the ATM-dependent DDR pathway with increased senescence and apoptosis in TBD patient cells. Pharmacologic ATM inhibition, modeling the effects of somatic ATM variants, selectively improved TBD cell fitness by allowing cells to bypass DDR-mediated senescence without detectably inducing chromosomal instability. Our results indicate that ATM-dependent DDR induced by telomere dysfunction is a key contributor to TBD pathogenesis and suggest dampening hyperactive ATM-dependent DDR as a potential therapeutic intervention.


  • Open Access

    Chronic Severe Neutropenia Associated With Intravenous Immunoglobulin for Multifocal Motor Neuropathy

    by Shannon Ugarte, Talia Gebhard, David R. Cornblath, Steven S. Scherer, Daria V. Babushok

    Intravenous immunoglobulin (IVIG) is an immunomodulatory therapy derived from pooled donor immunoglobulins and used for treatment of various autoimmune conditions. Here we report the diagnosis and management of IVIG‐induced chronic severe neutropenia with absolute neutrophil count 3/µL in a patient with multifocal motor neuropathy. Serial blood count showed a cyclical pattern of neutropenia: worsening 24–48 h post‐IVIG, then gradually improving before the next infusion. IVIG‐induced neutropenia is rare, with previous reports of predominantly mild transient neutropenia. Our case describes chronic severe neutropenia that developed years after starting IVIG. We summarize available evidence and management strategies for IVIG‐associated neutropenia.